Standard

Profiling of non-criteria antiphospholipid antibodies in patients with SLE : differentiation of thrombotic SLE patients and risk of recurrence of thrombosis. / Tkachenko, O; Lapin, S; Mazing, A; Emanuel, V; Belolipetskaia, E; Beliaeva, I; Myachikova, V; Maslyansky, A; Schierack, P; Roggenbuck, D.

In: Lupus, Vol. 29, No. 5, 04.2020, p. 490-498.

Research output: Contribution to journalArticlepeer-review

Harvard

Tkachenko, O, Lapin, S, Mazing, A, Emanuel, V, Belolipetskaia, E, Beliaeva, I, Myachikova, V, Maslyansky, A, Schierack, P & Roggenbuck, D 2020, 'Profiling of non-criteria antiphospholipid antibodies in patients with SLE: differentiation of thrombotic SLE patients and risk of recurrence of thrombosis', Lupus, vol. 29, no. 5, pp. 490-498. https://doi.org/10.1177/0961203320909952

APA

Tkachenko, O., Lapin, S., Mazing, A., Emanuel, V., Belolipetskaia, E., Beliaeva, I., Myachikova, V., Maslyansky, A., Schierack, P., & Roggenbuck, D. (2020). Profiling of non-criteria antiphospholipid antibodies in patients with SLE: differentiation of thrombotic SLE patients and risk of recurrence of thrombosis. Lupus, 29(5), 490-498. https://doi.org/10.1177/0961203320909952

Vancouver

Author

Tkachenko, O ; Lapin, S ; Mazing, A ; Emanuel, V ; Belolipetskaia, E ; Beliaeva, I ; Myachikova, V ; Maslyansky, A ; Schierack, P ; Roggenbuck, D. / Profiling of non-criteria antiphospholipid antibodies in patients with SLE : differentiation of thrombotic SLE patients and risk of recurrence of thrombosis. In: Lupus. 2020 ; Vol. 29, No. 5. pp. 490-498.

BibTeX

@article{fcccbc4af058413a875b08bcf1e2e43f,
title = "Profiling of non-criteria antiphospholipid antibodies in patients with SLE: differentiation of thrombotic SLE patients and risk of recurrence of thrombosis",
abstract = "To reveal the clinical significance of criteria and non-criteria antiphospholipid antibodies detected by line immunoassay in comparison with ELISA, systemic lupus erythematosus patients with and without thrombotic events were investigated. Thus, 107 systemic lupus erythematosus patients (48% with deep vein thrombosis or/and arterial thrombosis) and 120 healthy donors were enrolled. Serum antiphospholipid antibodies were detected by ELISA (Orgentec Diagnostika, Germany) and line immunoassay (GA Generic Assays, Germany). Lupus anticoagulant and IgG to cardiolipin and β2GPI but not IgM as well as triple positivity by ELISA and line immunoassay were linked with thrombosis in systemic lupus erythematosus. IgG to phosphatidylinositol and phosphatidylserine by line immunoassay showed significantly higher levels in systemic lupus erythematosus with deep vein thrombosis/arterial thrombosis than without and were independent risk factors for deep vein thrombosis (odds ratio 3.9, 95% confidence interval 1.1, 13.2) and arterial thrombosis (odds ratio 5.1, 95% confidence interval 1.3, 19.8) as well as thrombosis (odds ratio 3.6, 95% confidence interval 1.1, 11.3) and recurrence thereof (odds ratio 6.9, 95% confidence interval 2.1, 22.6), respectively. The occurrence of >4 IgG antiphospholipid antibodies by line immunoassay was an independent risk factor for thrombosis (odds ratio 10.9, 95% confidence interval 1.2, 101.5), arterial thrombosis (odds ratio 14.6, 95% confidence interval 2.5, 86.3), deep vein thrombosis (odds ratio 5.8, 95% confidence interval 1.0, 32.4) and recurrence of thrombosis (odds ratio 35.9, 95% confidence interval 3.8, 342.8). Line immunoassay is a promising multiplex test for the simultaneous detection of criteria and non-criteria antiphospholipid antibodies. Profiling of antiphospholipid antibodies by line immunoassay can differentiate systemic lupus erythematosus patients with thrombosis from systemic lupus erythematosus patients without and assess the risk for thrombosis and recurrence thereof.",
keywords = "Adult, Antibodies, Antiphospholipid/blood, Antiphospholipid Syndrome/blood, Case-Control Studies, Female, Humans, Logistic Models, Lupus Coagulation Inhibitor/blood, Lupus Erythematosus, Systemic/blood, Male, Middle Aged, Phosphatidylserines/metabolism, Recurrence, Risk Factors, Venous Thrombosis/complications",
author = "O Tkachenko and S Lapin and A Mazing and V Emanuel and E Belolipetskaia and I Beliaeva and V Myachikova and A Maslyansky and P Schierack and D Roggenbuck",
year = "2020",
month = apr,
doi = "10.1177/0961203320909952",
language = "English",
volume = "29",
pages = "490--498",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE",
number = "5",

}

RIS

TY - JOUR

T1 - Profiling of non-criteria antiphospholipid antibodies in patients with SLE

T2 - differentiation of thrombotic SLE patients and risk of recurrence of thrombosis

AU - Tkachenko, O

AU - Lapin, S

AU - Mazing, A

AU - Emanuel, V

AU - Belolipetskaia, E

AU - Beliaeva, I

AU - Myachikova, V

AU - Maslyansky, A

AU - Schierack, P

AU - Roggenbuck, D

PY - 2020/4

Y1 - 2020/4

N2 - To reveal the clinical significance of criteria and non-criteria antiphospholipid antibodies detected by line immunoassay in comparison with ELISA, systemic lupus erythematosus patients with and without thrombotic events were investigated. Thus, 107 systemic lupus erythematosus patients (48% with deep vein thrombosis or/and arterial thrombosis) and 120 healthy donors were enrolled. Serum antiphospholipid antibodies were detected by ELISA (Orgentec Diagnostika, Germany) and line immunoassay (GA Generic Assays, Germany). Lupus anticoagulant and IgG to cardiolipin and β2GPI but not IgM as well as triple positivity by ELISA and line immunoassay were linked with thrombosis in systemic lupus erythematosus. IgG to phosphatidylinositol and phosphatidylserine by line immunoassay showed significantly higher levels in systemic lupus erythematosus with deep vein thrombosis/arterial thrombosis than without and were independent risk factors for deep vein thrombosis (odds ratio 3.9, 95% confidence interval 1.1, 13.2) and arterial thrombosis (odds ratio 5.1, 95% confidence interval 1.3, 19.8) as well as thrombosis (odds ratio 3.6, 95% confidence interval 1.1, 11.3) and recurrence thereof (odds ratio 6.9, 95% confidence interval 2.1, 22.6), respectively. The occurrence of >4 IgG antiphospholipid antibodies by line immunoassay was an independent risk factor for thrombosis (odds ratio 10.9, 95% confidence interval 1.2, 101.5), arterial thrombosis (odds ratio 14.6, 95% confidence interval 2.5, 86.3), deep vein thrombosis (odds ratio 5.8, 95% confidence interval 1.0, 32.4) and recurrence of thrombosis (odds ratio 35.9, 95% confidence interval 3.8, 342.8). Line immunoassay is a promising multiplex test for the simultaneous detection of criteria and non-criteria antiphospholipid antibodies. Profiling of antiphospholipid antibodies by line immunoassay can differentiate systemic lupus erythematosus patients with thrombosis from systemic lupus erythematosus patients without and assess the risk for thrombosis and recurrence thereof.

AB - To reveal the clinical significance of criteria and non-criteria antiphospholipid antibodies detected by line immunoassay in comparison with ELISA, systemic lupus erythematosus patients with and without thrombotic events were investigated. Thus, 107 systemic lupus erythematosus patients (48% with deep vein thrombosis or/and arterial thrombosis) and 120 healthy donors were enrolled. Serum antiphospholipid antibodies were detected by ELISA (Orgentec Diagnostika, Germany) and line immunoassay (GA Generic Assays, Germany). Lupus anticoagulant and IgG to cardiolipin and β2GPI but not IgM as well as triple positivity by ELISA and line immunoassay were linked with thrombosis in systemic lupus erythematosus. IgG to phosphatidylinositol and phosphatidylserine by line immunoassay showed significantly higher levels in systemic lupus erythematosus with deep vein thrombosis/arterial thrombosis than without and were independent risk factors for deep vein thrombosis (odds ratio 3.9, 95% confidence interval 1.1, 13.2) and arterial thrombosis (odds ratio 5.1, 95% confidence interval 1.3, 19.8) as well as thrombosis (odds ratio 3.6, 95% confidence interval 1.1, 11.3) and recurrence thereof (odds ratio 6.9, 95% confidence interval 2.1, 22.6), respectively. The occurrence of >4 IgG antiphospholipid antibodies by line immunoassay was an independent risk factor for thrombosis (odds ratio 10.9, 95% confidence interval 1.2, 101.5), arterial thrombosis (odds ratio 14.6, 95% confidence interval 2.5, 86.3), deep vein thrombosis (odds ratio 5.8, 95% confidence interval 1.0, 32.4) and recurrence of thrombosis (odds ratio 35.9, 95% confidence interval 3.8, 342.8). Line immunoassay is a promising multiplex test for the simultaneous detection of criteria and non-criteria antiphospholipid antibodies. Profiling of antiphospholipid antibodies by line immunoassay can differentiate systemic lupus erythematosus patients with thrombosis from systemic lupus erythematosus patients without and assess the risk for thrombosis and recurrence thereof.

KW - Adult

KW - Antibodies, Antiphospholipid/blood

KW - Antiphospholipid Syndrome/blood

KW - Case-Control Studies

KW - Female

KW - Humans

KW - Logistic Models

KW - Lupus Coagulation Inhibitor/blood

KW - Lupus Erythematosus, Systemic/blood

KW - Male

KW - Middle Aged

KW - Phosphatidylserines/metabolism

KW - Recurrence

KW - Risk Factors

KW - Venous Thrombosis/complications

U2 - 10.1177/0961203320909952

DO - 10.1177/0961203320909952

M3 - Article

C2 - 32131675

VL - 29

SP - 490

EP - 498

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 5

ER -

ID: 100706687